MA-FORRESTER
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2024 global Technology Awards in two categories: Technology Strategy Impact and Enterprise Architecture. These awards recognize organizations that align their technology strategies to their business goals, are quick to adapt to changing market conditions, and focus on building customer trust. Strong alignment is critical to business results: According to Forrester, firms with strong alignment grow 2.4 times faster than peers and have twice the profitability.
Nomination criteria for Forrester’s Technology Awards are as follows:
- Technology Strategy Impact. Award recipients must execute a high-performance IT strategy, which Forrester defines as the pursuit of continuous improvement of business results through technology. Recipients must also demonstrate how they use alignment, trust, and adaptivity to enhance business outcomes with their IT capabilities.
- Enterprise Architecture. This award, presented in partnership with The Open Group — author of the TOGAF® standard, developed by The Open Group Architecture Forum — recognizes organizations that demonstrate how their outcome-driven enterprise architecture (EA) practice fuels change, growth, and differentiation. Organizations must also show how their EA practice helps their firm manage risk, drive cost efficiency, improve customer experience, and increase revenue.
Nominations for both award categories are open to organizations with 1,000 or more employees that are using technology to improve business outcomes. Technology leaders — including chief information officers, chief technology officers, chief digital officers, and enterprise architects across North America; Europe, the Middle East, and Africa (EMEA); and Asia Pacific (APAC) — are encouraged to apply.
Additional details on how to apply for Forrester’s 2024 Technology Awards:
- North America. Organizations in North America can visit here, with an awards submission deadline of May 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit North America, being held in Austin, Texas, and digitally, September 9–12, 2024.
- EMEA. Organizations in EMEA can visit here, with an awards submission deadline of June 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit EMEA, being held in London and digitally, October 9–11, 2024.
- Asia Pacific. Organizations in APAC can visit here, with an awards submission deadline of July 9, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit APAC, being held in Sydney and digitally, October 29, 2024.
“Forrester’s Technology Awards will honor organizations that continually pursue the improvement of business results through technology,” said Laura Koetzle, vice president and group research director at Forrester. “These organizations embody the three guiding principles of high-performance IT strategy: alignment, trust, and adaptivity.”
“Enterprise architecture plays a critical role in driving growth and making a tangible difference in business outcomes. By identifying and describing the future and current state of the enterprise, EA provides one of the most effective ways to realize the organization’s objectives. Recognizing and celebrating EA practices and initiatives around the world has never been more important,” said Steve Nunn, president and CEO of The Open Group.
Resources:
- Learn more about Forrester’s 2024 Technology Awards program.
- Register to attend Forrester’s Technology & Innovation Summits 2024 in North America, EMEA, and APAC.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205913561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom